MCID: ORL011
MIFTS: 56

Oral Cancer malady

Categories: Rare diseases, Oral diseases, Cancer diseases

Aliases & Classifications for Oral Cancer

Aliases & Descriptions for Oral Cancer:

Name: Oral Cancer 50 52 41 3
Lip and Oral Cavity Carcinoma 69
Malignant Neoplasm of Mouth 69

Classifications:



Summaries for Oral Cancer

MedlinePlus : 41 oral cancer can form in any part of the mouth. most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have hpv, or have a history of head or neck cancer. frequent sun exposure is also a risk factor for lip cancer. symptoms of oral cancer include white or red patches in your mouth a mouth sore that won't heal bleeding in your mouth loose teeth problems or pain with swallowing a lump in your neck an earache tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. oral cancer treatments may include surgery, radiation therapy, and chemotherapy. some patients have a combination of treatments. nih: national cancer institute

MalaCards based summary : Oral Cancer, also known as lip and oral cavity carcinoma, is related to oral squamous cell carcinoma and oral submucous fibrosis, and has symptoms including halitosis and snoring. An important gene associated with Oral Cancer is ORAOV1 (Oral Cancer Overexpressed 1), and among its related pathways/superpathways are Glioma and Development Endothelin-1/EDNRA signaling. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include tongue, testes and lymph node, and related phenotypes are cardiovascular system and growth/size/body region

NIH Rare Diseases : 50 oral cancer includes cancers of the mouth, lips, and oropharynx (the part of the throat at the back of the mouth). most cases are designated as squamous cell carcinomas because they begin in the flat cells (squamous cells) that cover the surfaces of the mouth, tongue, and lips. about 42,000 individuals in the united stated are diagnosed with oral cancer each year. most cases occur in people over age 40. men are twice as likely to be affected as women. the use of alcohol and/or tobacco is associated with approximately 75 percent of oral cancers. other risk factors include hpv, a sexually transmitted disease; increasing age; sun exposure; and a poor diet. treatment for oral cancer may include surgery, radiation therapy, chemotherapy, or targeted therapy. last updated: 6/21/2016

Wikipedia : 71 Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue... more...

Related Diseases for Oral Cancer

Diseases related to Oral Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
id Related Disease Score Top Affiliating Genes
1 oral squamous cell carcinoma 29.8 CDH1 EGFR PTGS2 TP53
2 oral submucous fibrosis 11.0
3 oral lichen planus 11.0
4 geographic tongue 10.7
5 linitis plastica 10.4 CDH1 TP53
6 clear cell adenofibroma 10.3 CDKN2A TP53
7 wolffian adnexal neoplasm 10.3 EGFR TP53
8 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
9 facio skeletal genital syndrome rippberger type 10.3 MMP2 MMP9
10 skeletal tuberculosis 10.3 CCND1 CDKN2A
11 brain stem medulloblastoma 10.3 CCND1 CDKN2A TP53
12 cervical verrucous carcinoma 10.3 CCND1 CDKN2A TP53
13 chondrodysplasia punctata, rhizomelic, type 3 10.3 CASP3 TP53
14 his bundle tachycardia 10.3 CCND1 EGFR TP53
15 chronic monocytic leukemia 10.3 CDKN2A EGFR TP53
16 chondrodysplasia punctata, rhizomelic, type 1 10.2 CDH1 MMP9 PTGS2
17 retroperitoneal sarcoma 10.2 CASP3 GSTM1 GSTT1
18 mycobacterium kansasii 10.2 CCND1 GSTM1 GSTT1 TP53
19 reactive arthritis 10.2 EGFR PTGS2 TP53
20 myxedema 10.2 CDKN2A EGFR TP53
21 pituitary stalk meningioma 10.2 GSTM1 GSTT1 TP53
22 thymus adenocarcinoma 10.2 EGFR MMP2 MMP9
23 acquired hemangioma 10.2 CDKN2A PTGS2 TP53
24 cleft palate cardiac defect ectrodactyly 10.2 CCND1 EGFR TP53
25 urethral verrucous carcinoma 10.2 CDKN2A PTGS2 TP53
26 allergic contact dermatitis 10.2 CDKN2A EGFR TP53
27 fallopian tube leiomyosarcoma 10.2 CDH1 CDKN2A TP53
28 brachydactyly tibial hypoplasia 10.2 CCND1 CDKN2A PTGS2
29 secondary corneal edema 10.2 CYP1A1 KRT19 TP53
30 maxillary neoplasm 10.2 CDH1 MMP2 MMP9
31 pityriasis rosea 10.2 CDKN2A EGFR TP53
32 active vestibular meniere's disease 10.2 CCND1 CDKN2A PTGS2
33 breast papillary carcinoma 10.2 CDH1 MMP2 MMP9
34 senile atrophy of choroid 10.2 CASP3 MMP2 MMP9
35 rapsn-related fetal akinesia deformation sequence 10.2 CDH1 CYP1A1 GSTM1 GSTT1
36 interstitial lung disease 10.2 CDKN2A EGFR TP53
37 tamoxifen-related endometrial lesion 10.2 CDKN2A PTGS2 TP53
38 extrahepatic cholestasis 10.2 ANO1 KRT13
39 oro-mandibular-limb hypogenesis syndrome 10.2 CCND1 CDKN2A GSTM1 TP53
40 uvula cancer 10.2 CYP1A1 EGFR GSTM1 GSTT1
41 extraocular retinoblastoma 10.2 CCND1 CDKN2A TP53
42 sengers syndrome 10.2 CDH1 CDKN2A EGFR
43 anal carcinoma in situ 10.2 CDKN2A KRT19 TP53
44 tricuspid valve prolapse 10.2 CDKN2A EGFR PTGS2
45 basophilic carcinoma 10.2 CDH1 KRT19 TP53
46 adult acute lymphocytic leukemia 10.2 CDKN2A GSTM1 GSTT1 TP53
47 integumentary system benign neoplasm 10.2 CCND1 CDKN2A TP53
48 ossifying fibromyxoid tumor 10.2 CDKN2A KRT19 TP53
49 adenoid squamous cell carcinoma 10.2 CDKN2A MMP2 MMP9
50 papillary transitional carcinoma 10.2 CASP3 CCND1 CDH1 TP53

Graphical network of the top 20 diseases related to Oral Cancer:



Diseases related to Oral Cancer

Symptoms & Phenotypes for Oral Cancer

UMLS symptoms related to Oral Cancer:


halitosis, snoring

MGI Mouse Phenotypes related to Oral Cancer:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 ANO1 CASP3 CCND1 CDH1 CDKN2A CYP1A1
2 growth/size/body region MP:0005378 10.38 ANO1 CASP3 CCND1 CDH1 CDK2AP1 CDKN2A
3 mortality/aging MP:0010768 10.37 SLC7A5 TP53 ANO1 CASP3 CCND1 CDH1
4 cellular MP:0005384 10.32 CASP3 CCND1 CDH1 CDK2AP1 CDKN2A EGFR
5 digestive/alimentary MP:0005381 10.27 TP53 CASP3 CCND1 CDH1 CDKN2A EGFR
6 immune system MP:0005387 10.26 MMP2 MMP9 CASP3 CCND1 CDH1 CDKN2A
7 endocrine/exocrine gland MP:0005379 10.25 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
8 integument MP:0010771 10.21 ANO1 CASP3 CCND1 CDH1 CDKN2A EGFR
9 nervous system MP:0003631 10.21 MMP9 PTGS2 RARB SLC7A5 TP53 ANO1
10 embryo MP:0005380 10.16 CDH1 CDK2AP1 CDKN2A EGFR KRT19 PTGS2
11 muscle MP:0005369 10.13 ANO1 CASP3 CDKN2A EGFR MMP2 MMP9
12 craniofacial MP:0005382 10.12 CASP3 CCND1 CDK2AP1 EGFR MMP2 RARB
13 neoplasm MP:0002006 10.11 CCND1 CDH1 CDKN2A EGFR KRT19 MMP2
14 normal MP:0002873 10.02 CCND1 CDH1 CYP1A1 EGFR KRT19 MMP2
15 no phenotypic analysis MP:0003012 10.01 CASP3 CDH1 CDKN2A CYP1A1 EGFR KRT19
16 reproductive system MP:0005389 9.96 PTGS2 RARB TP53 CASP3 CCND1 CDH1
17 renal/urinary system MP:0005367 9.87 RARB TP53 ANO1 CASP3 EGFR MMP9
18 respiratory system MP:0005388 9.85 ANO1 CASP3 CCND1 CDKN2A EGFR MMP2
19 skeleton MP:0005390 9.73 TP53 ANO1 CASP3 CCND1 CDKN2A EGFR
20 vision/eye MP:0005391 9.28 CASP3 CCND1 CDKN2A EGFR MMP2 MMP9

Drugs & Therapeutics for Oral Cancer

Drugs for Oral Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1132)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Pravastatin Approved Phase 4 81093-37-0 54687
5
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
6
Aspirin Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-78-2 2244
7
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 50-28-2 5757 53477783
8
Vinblastine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 865-21-4 13342 241903
9
Digoxin Approved Phase 4,Phase 2,Phase 1 20830-75-5 30322 2724385
10
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
11
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
12
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 71486-22-1 60780 44424639
13
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
14
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
15
Erythromycin Approved, Vet_approved Phase 4,Phase 2,Phase 1 114-07-8 12560
16
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
17
Diclofenac Approved, Vet_approved Phase 4,Phase 2 15307-86-5 3033
18
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85721-33-1 2764
19
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 57-27-2 5288826
20
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
21
Gefitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 184475-35-2 123631
22
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
23
Ribavirin Approved Phase 4,Phase 1,Phase 2 36791-04-5 37542
24
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
25
Naloxone Approved, Vet_approved Phase 4,Phase 3 465-65-6 5284596
26
Copper Approved Phase 4,Phase 2,Phase 1 15158-11-9, 7440-50-8 27099
27
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
28
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
30
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
31
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
32
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
33
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
34
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
35
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
36 Tegafur Approved Phase 4,Phase 3,Phase 1,Phase 2 17902-23-7
37
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
38
Sucralfate Approved Phase 4,Phase 3 54182-58-0
39
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 20537-88-6 2141
40
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
41
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 76-42-6 5284603
42
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 1 466-99-9 5284570
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 437-38-7 3345
44
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
45
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
46
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
47
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
48
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
49
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
50
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
2 rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors Unknown status NCT00902083 Phase 4
3 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4
4 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
5 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4
6 Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia Unknown status NCT02243735 Phase 4
7 Paracetamol for Cancer Pain Unknown status NCT01313247 Phase 4
8 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
9 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
10 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4
11 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
12 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
13 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4
14 p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage Unknown status NCT00894153 Phase 4
15 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
16 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4
17 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4
18 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
19 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
20 An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer Completed NCT01006356 Phase 4
21 An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain Completed NCT00766831 Phase 4
22 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
23 Absorption of Orally Ingested Phosphate in Refeeding Syndrome Completed NCT02880072 Phase 4
24 Enteral Nutrition Support in Children and Adolescents With Cancer Completed NCT01426750 Phase 4
25 Enteral Nutrition in Cancer Patients Completed NCT01304446 Phase 4
26 Enteral Nutrition in Cancer Patient Completed NCT01302509 Phase 4
27 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4
28 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4
29 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
30 A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer Completed NCT02581423 Phase 4
31 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4
32 Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients Completed NCT01621100 Phase 4
33 Mouth Care Regimes During Radiotherapy Completed NCT00138827 Phase 4
34 Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Completed NCT00082277 Phase 4
35 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4
36 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4
37 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
38 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4
39 Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy Completed NCT00224068 Phase 4
40 Effects of Garlic Supplements on Opioids in Healthy Volunteers Completed NCT00499460 Phase 4
41 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4
42 RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients Completed NCT01401075 Phase 4
43 A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval Completed NCT01328054 Phase 4
44 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4
45 Oral Contraceptive and Cardiovascular Risk in PCOS Completed NCT00593294 Phase 4
46 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4
47 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4
48 XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Completed NCT00127933 Phase 4
49 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4
50 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4

Search NIH Clinical Center for Oral Cancer

Genetic Tests for Oral Cancer

Anatomical Context for Oral Cancer

MalaCards organs/tissues related to Oral Cancer:

39
Tongue, Testes, Lymph Node, Endothelial, Lung, Bone, T Cells

Publications for Oral Cancer

Articles related to Oral Cancer:

(show top 50) (show all 1197)
id Title Authors Year
1
MiR-214 regulates oral cancer KB cell apoptosis through targeting RASSF5. ( 28290615 )
2017
2
May High MMP-2 and TIMP-2 Expressions Increase or Decrease the Aggressivity of Oral Cancer? ( 27853937 )
2017
3
FADS1 rs174549 Polymorphism May Predict a Favorable Response to Chemoradiotherapy in Oral Cancer Patients. ( 27542551 )
2017
4
Hypermethylation of IFN-I^ in oral cancer tissues. ( 28091876 )
2017
5
Referrals to dentists by GPs could delay diagnosis of oral cancer. ( 28073743 )
2017
6
Role of Monocyte Count and Neutrophil-to-Lymphocyte Ratio in Survival of Oral Cancer Patients. ( 28050203 )
2017
7
The emerging role of long noncoding RNAs in oral cancer. ( 27989708 )
2017
8
Next-generation Sequencing for microRNA Profiling: MicroRNA-21-3p Promotes Oral Cancer Metastasis. ( 28314265 )
2017
9
Reply to GalvALo-Moreira and da Cruz: Saliva biomarkers to complement the visualization-based oral cancer detection. ( 28039437 )
2017
10
Population-based screening program for reducing oral cancer mortality in 2,334,299 Taiwanese cigarette smokers and/or betel quid chewers. ( 28055109 )
2017
11
Nanoparticle delivery of Wnt-1 siRNA enhances photodynamic therapy by inhibiting epithelial-mesenchymal transition for oral cancer. ( 28070573 )
2017
12
Effect on Quality of Life in Oral Cancer Patients after Radiation and Chemotherapy. ( 27206995 )
2016
13
Association of Genetic Polymorphism in the Interleukin-8 Gene with Risk of Oral Cancer and Its Correlation with Pain. ( 26660080 )
2016
14
Tumor Growth and Cell Proliferation Rate in Human Oral Cancer. ( 27664486 )
2016
15
A Survey of Oral Cancer Screening Insurance Coverage in New York City. ( 27209714 )
2016
16
p16 - a Possible Surrogate Marker for High-Risk Human Papillomaviruses in Oral Cancer? ( 27644660 )
2016
17
Functional polymorphisms in the IL-10 gene with susceptibility to esophageal, nasopharyngeal, and oral cancers. ( 27002767 )
2016
18
MicroRNA and target gene expression based clustering of oral cancer, precancer and normal tissues. ( 27515006 )
2016
19
Nanostructured zirconia decorated reduced graphene oxide based efficient biosensing platform for non-invasive oral cancer detection. ( 26657594 )
2016
20
Combination of genetic variants in cyclin D1 and retinoblastoma genes predict clinical outcome in oral cancer patients. ( 26459309 )
2016
21
Reliability of the pectoralis major myocutaneous flap in reconstructive oral cancer surgery in developing countries: Our experience. ( 28050062 )
2016
22
Butanol-Partitioned Extraction from Aqueous Extract of Gracilaria tenuistipitata Inhibits Cell Proliferation of Oral Cancer Cells Involving Apoptosis and Oxidative Stress. ( 27138906 )
2016
23
Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3-IP chain down-regulation via caspase-3 activation in oral cancer. ( 26595239 )
2016
24
AAOM Clinical Practice Statement: Subject: Oral lichen planus and oral cancer. ( 27492565 )
2016
25
Fabrication of a complete, removable dental prosthesis from a digital intraoral impression for a patient with an excessively tight reconstructed lip after oral cancer treatment: A clinical report. ( 27646801 )
2016
26
Intratumoral photodynamic therapy with newly synthesized Pheophorbide a in murine oral cancer. ( 27629775 )
2016
27
Grainyhead-like 2 regulates epithelial plasticity and stemness in oral cancer cells. ( 26933170 )
2016
28
Down-regulation of I^-catenin and the associated migration ability by Taiwanin C in arecoline and 4-NQO-induced oral cancer cells via GSK-3I^ activation. ( 27648737 )
2016
29
Junk DNA: Prospects for Oral Cancer Research. ( 27207194 )
2016
30
Improving public awareness and outcomes for oral cancer. ( 28031950 )
2016
31
Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation. ( 27155849 )
2016
32
Pyruvic acid levels in serum and saliva: A new course for oral cancer screening? ( 27194870 )
2016
33
Oral cancer: exploring the stories in United Kingdom newspaper articles. ( 27608578 )
2016
34
PBK/TOPK Expression Predicts Prognosis in Oral Cancer. ( 27347940 )
2016
35
An audit of CT chest surveillance following oral cancer treatment. ( 27156437 )
2016
36
Interventions for treating oral leukoplakia to prevent oral cancer. ( 27471845 )
2016
37
Association of DNA sequence variation in mitochondrial DNA polymerase with mitochondrial DNA synthesis and risk of oral cancer. ( 26403317 )
2016
38
Oral cancer incidence and survival rates in the Republic of Ireland, 1994-2009. ( 27993131 )
2016
39
Kochia scoparia induces apoptosis of oral cancer cells in vitro and in heterotopic tumors. ( 27616033 )
2016
40
Genetic Abnormalities in Oral Leukoplakia and Oral Cancer Progression. ( 27356725 )
2016
41
Surgical margins for the extirpation of oral cancer. ( 28053901 )
2016
42
Salivary Amylase as a Marker of Salivary Gland Function in Patients Undergoing Radiotherapy for Oral Cancer. ( 27637993 )
2016
43
Discovery of potential serum protein biomarkers for lymph node metastasis in oral cancer. ( 25223295 )
2016
44
Oral cancer: Breath of death. ( 27608554 )
2016
45
Amplification and protein overexpression of cyclin D1: Predictor of occult nodal metastasis in early oral cancer. ( 27653309 )
2016
46
Polymorphisms in methylenetetrahydrofolate reductase and cystathionine beta-synthase in oral cancer - a case-control study in southeastern Brazilians. ( 26749456 )
2016
47
Roe Protein Hydrolysates of Giant Grouper (Epinephelus lanceolatus) Inhibit Cell Proliferation of Oral Cancer Cells Involving Apoptosis and Oxidative Stress. ( 27195297 )
2016
48
Assessment of duration until initial treatment and its determining factors among newly diagnosed oral cancer patients: A population-based retrospective cohort study. ( 27977607 )
2016
49
Prospective study on factors affecting the prognosis of oral cancer in a Chinese population. ( 28032596 )
2016
50
Association of CYP1A1 MspI polymorphism with oral cancer risk in Asian populations: a meta-analysis. ( 27323067 )
2016

Variations for Oral Cancer

Cosmic variations for Oral Cancer:

9 (show top 50) (show all 508)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 7
2 COSM44310 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.738G>A p.M246I 7
3 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 7
4 COSM11196 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>T p.G245V 7
5 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 7
6 COSM44393 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.821T>C p.V274A 7
7 COSM43582 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.454C>T p.P152S 7
8 COSM44226 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.380C>T p.S127F 7
9 COSM10654 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.637C>T p.R213* 7
10 COSM10704 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>T p.R282W 7
11 COSM10672 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.577C>T p.H193Y 7
12 COSM10941 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.730G>A p.G244S 7
13 COSM10656 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.742C>T p.R248W 7
14 COSM10728 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>A p.R280K 7
15 COSM43635 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>T p.H179L 7
16 COSM44126 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.507G>A p.M169I 7
17 COSM10790 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.455C>T p.P152L 7
18 COSM43868 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.689C>T p.T230I 7
19 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 7
20 COSM44091 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.746G>A p.R249K 7
21 COSM11063 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>T p.M237I 7
22 COSM44577 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.921A>G p.A307A 7
23 COSM10834 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>A p.M237I 7
24 COSM45099 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.924G>A p.L308L 7
25 COSM10867 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>A p.G266E 7
26 COSM11073 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 7
27 COSM44428 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.741C>T p.N247N 7
28 COSM43621 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.809T>G p.F270C 7
29 COSM10663 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.916C>T p.R306* 7
30 COSM10886 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 7
31 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 7
32 COSM10726 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.856G>A p.E286K 7
33 COSM45046 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.542G>C p.R181P 7
34 COSM44415 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>C p.M237I 7
35 COSM10756 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.827C>T p.A276V 7
36 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 7
37 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 7
38 COSM43743 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.914A>G p.K305R 7
39 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 7
40 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 7
41 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 7
42 COSM45353 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.673G>A p.V225I 7
43 COSM43801 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.716A>C p.N239T 7
44 COSM43632 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.493C>T p.Q165* 7
45 COSM10891 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>A p.V272M 7
46 COSM45077 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.390C>T p.L130L 7
47 COSM10889 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>G p.H179R 7
48 COSM44639 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.869G>T p.R290L 7
49 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 7
50 COSM44262 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.808T>C p.F270L 7

Copy number variations for Oral Cancer from CNVD:

7 (show top 50) (show all 92)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 16000 1 120982663 144003083 Loss Oral cancer
2 18683 1 147134204 147499075 Loss Oral cancer
3 22566 1 167493797 167507911 Loss NME7 Oral cancer
4 25915 1 195026732 195048237 Gain Oral cancer
5 25916 1 195026732 195104236 Gain Oral cancer
6 30920 1 246713386 246852155 Loss Oral cancer
7 35162 1 604268 4312064 Gain Oral cancer
8 41154 10 138235 42150788 Loss Oral cancer
9 42635 10 37475290 37508431 Loss Oral cancer
10 43408 10 46396192 46516611 Loss Oral cancer
11 48616 11 101407278 102165885 Gain Oral cancer
12 49060 11 102611683 110151240 Loss Oral cancer
13 50726 11 119044645 133316524 Loss Oral cancer
14 52672 11 186966 2789993 Gain Oral cancer
15 55431 11 52900000 134452384 Gain Oral cancer
16 56752 11 60970713 78077527 Gain Oral cancer
17 58595 11 68654476 70150073 Gain Oral cancer
18 79103 13 6365 44752 Loss Oral cancer
19 82813 14 15600000 106368585 Gain Oral cancer
20 83220 14 19560721 22142166 Gain Oral cancer
21 83591 14 21538460 22005864 Gain Oral cancer
22 85535 14 48265939 80627188 Gain Oral cancer
23 88199 14 87604117 106349785 Gain Oral cancer
24 89600 15 18741744 19805989 Loss Oral cancer
25 89601 15 18741744 20060090 Gain Oral cancer
26 101423 16 36766 2592859 Gain Oral cancer
27 106087 16 85963377 88690615 Gain Oral cancer
28 118416 17 77385789 78462808 Gain Oral cancer
29 120365 18 24990733 76110993 Loss Oral cancer
30 124096 19 1 28500000 Gain Oral cancer
31 127007 19 232109 258746 Gain Oral cancer
32 133960 19 8275 236875 Loss Oral cancer
33 136827 2 133504494 133812256 Loss NCKAP5 Oral cancer
34 144179 2 242501268 242717042 Gain Oral cancer
35 150414 20 1 27100000 Gain Oral cancer
36 151218 20 18609 5869816 Gain Oral cancer
37 151741 20 24728423 25680524 Gain Oral cancer
38 152139 20 29436566 62363603 Gain Oral cancer
39 155361 20 55096989 59483462 Gain Oral cancer
40 155973 20 59483462 62194881 Gain Oral cancer
41 160312 22 134684 14797037 Loss Oral cancer
42 164561 22 37689087 37715408 Loss Oral cancer
43 166146 3 1 91700000 Deletion Oral cancer
44 166162 3 1 91700000 Loss Oral cancer
45 167591 3 121355348 144551988 Gain Oral cancer
46 169747 3 145187343 199379595 Gain Oral cancer
47 171086 3 163941201 164138371 Loss Oral cancer
48 172647 3 185019156 185896384 Gain Oral cancer
49 175342 3 39095 9150490 Loss CHL1 Oral cancer
50 175343 3 39095 9150490 Loss GRM7 Oral cancer

Expression for Oral Cancer

Search GEO for disease gene expression data for Oral Cancer.

Pathways for Oral Cancer

Pathways related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 41)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 CCND1 CDH1 CDKN2A EGFR MMP2 MMP9
2
Show member pathways
12.77 CASP3 CCND1 EGFR MMP2 MMP9
3
Show member pathways
12.63 CYP1A1 GSTM1 GSTM3 GSTT1 PTGS2
4
Show member pathways
12.5 CASP3 CCND1 CDH1 EGFR MMP2 MMP9
5 12.45 CASP3 CCND1 CDKN2A EGFR MMP9 PTGS2
6
Show member pathways
12.34 CASP3 CCND1 CDKN2A TP53
7
Show member pathways
12.34 CASP3 CCND1 CDH1 EGFR TP53
8 12.33 CCND1 CDH1 CDKN2A TP53
9 12.27 CASP3 CCND1 CDKN2A TP53
10 12.26 CASP3 CCND1 EGFR MMP2 MMP9 TP53
11 12.25 CASP3 CCND1 CDH1 CDKN2A EGFR MMP2
12
Show member pathways
12.16 CASP3 CCND1 EGFR TP53
13 12.12 CASP3 CCND1 CDH1 EGFR TP53
14
Show member pathways
12.08 CCND1 CDKN2A EGFR TP53
15 12.02 GSTM1 GSTM3 GSTT1 MMP2 MMP9 TP53
16 11.98 CASP3 CCND1 CDH1 EGFR MMP2 MMP9
17 11.96 CCND1 CDKN2A EGFR TP53
18 11.95 CCND1 MMP2 MMP9 PTGS2 TP53
19 11.88 CASP3 CCND1 EGFR MMP9 PTGS2 TP53
20 11.81 CCND1 PTGS2 RARB TP53
21 11.8 MMP2 MMP9 PTGS2
22 11.77 CCND1 CDH1 MMP2 MMP9
23
Show member pathways